Eli Lilly and Company

Last modified by Asif Farooqui on 2023/12/18 17:42

Contents

Summary
Recent Developments
Financial Highlights
Company Overview
- Products
- Company History
References

Summary

Eli Lilly and Company is a major American pharmaceutical company with a global reach.
Manufacturing plants located in 7 countries and Products marketed in approximately 110 countries.
Lilly to expand injectable manufacturing capacity in Germany.

Eli Lilly and Company (NYSE: LLY) is a major American pharmaceutical company with a global reach. Lilly was founded in 1876 by Colonel Eli Lilly. Manufacturing plants located in 7 countries and Products marketed in approximately 110 countries.

Recent Developments

Lilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego¹

November 28, 2023; Eli Lilly and Company announced plans to open its first-ever Lilly Gateway Labs location in San Diego, Calif. in the first half of 2024. Gateway Labs is Lilly's shared innovation accelerator that provides participating companies with state-of-the-art lab space and unique access to Lilly scientists, researchers and executives, as well as exposure to Lilly's functional and scientific expertise. This will be the company's third Gateway Labs location, with additional sites located in San Francisco and Boston.

The new site will be located in Alexandria's University Town Center (UTC) campus, and offer nearly 62,000 square feet of rentable, flexibly-designed lab space, as well as open workstations for fostering scientific exchange and collaboration among participating companies. It is expected to accommodate 10 companies and more than 120 biotech and Lilly employees.

Lilly to expand injectable manufacturing capacity in Germany.²

November 17, 2023; Eli Lilly and Company announced plans to construct a new $2.5 billion high-tech manufacturing site in Alzey, Rhineland-Palatinate, Germany. This new facility will further expand the company's global parenteral (injectable) product and device manufacturing network and support an increased demand for Lilly's medicines, including its diabetes and obesity portfolio. The company has launched 21 treatments since 2014 and plans to launch several more in the coming years.

With the planned manufacturing facility in Alzey, Lilly will operate a total of six manufacturing sites in Europe, including one in nearby Fegersheim, France. Lilly's ongoing investments in Europe will create operational synergies, strengthen university and government relationships, support the early-stage life science ecosystem, and diversify the growing Lilly presence in Europe.

Financial Highlights

Third-Quarter 2023 Results³

Q3 2023, worldwide revenue was $9.50 billion, an increase of 37% compared with Q3 2022, driven by increases of 31% in volume, 6% due to higher realized prices, and 1% from the favorable impact of foreign exchange rates. The volume increase was primarily driven by $1.42 billion from the sale of rights for the olanzapine portfolio (Zyprexa®), and volume growth from Verzenio®, Mounjaro®, Jardiance, Taltz® and Trulicity®, partially offset by the absence of COVID-19 antibodies revenue in 2023. Excluding revenue from the olanzapine portfolio and the $386.6 million of COVID-19 antibodies sales in 2022, revenue in Q3 2023 increased 24%. New Products contributed $1.44 billion to revenue in Q3 2023. Growth Products revenue increased 12% to $4.96 billion in Q3 2023. Higher realized prices were primarily driven by Mounjaro savings card dynamics, partially offset by Trulicity.

Revenue in the U.S. increased 21% to $5.37 billion, driven by a 13% increase in realized prices and a 9% increase in volume. The higher realized prices in the U.S. were driven by Mounjaro savings card dynamics, partially offset by lower realized prices for Trulicity. When excluding Mounjaro, U.S. price declined high-single digits for the quarter. The increase in U.S. volume was driven by Mounjaro, Verzenio, Trulicity, Jardiance and Taltz, partially offset by the absence of revenue from COVID-19 antibodies in 2023. Excluding revenue from the olanzapine portfolio and COVID-19 antibodies, U.S. revenue increased 32%.

Revenue outside the U.S. increased 64% to $4.13 billion, driven by a 69% increase in volume and a 2% increase from the favorable impact of foreign exchange rates, partially offset by a 7% decrease due to lower realized prices. The increase in volume outside the U.S. was largely driven by the sale of rights for the olanzapine portfolio, as well as increased volume for Verzenio, Jardiance and Taltz. The lower realized prices were primarily driven by a new supply arrangement associated with the sale of rights for the olanzapine portfolio. Excluding revenue from the olanzapine portfolio, revenue outside the U.S. increased 10%.

Gross margin increased 42% to $7.64 billion in Q3 2023. Gross margin as a percent of revenue was 80.4%, an increase of 3.1 percentage points. The increase in gross margin percent was primarily driven by the sale of rights for the olanzapine portfolio and the absence of COVID-19 antibodies sales in Q3 2023, as well as higher realized prices, partially offset by increased manufacturing expenses related to labor costs and investments in capacity expansion.

In Q3 2023, research and development expenses increased 34% to $2.41 billion, or 25% of revenue, primarily driven by higher development expenses for late-stage assets and additional investments in early-stage research.

Marketing, selling and administrative expenses increased 12% to $1.80 billion in Q3 2023, primarily driven by costs associated with launches of new products and indications, as well as compensation and benefits costs.

Q3 2023, net income (loss) and earnings (loss) per share were $(57.4) million and $(0.06), respectively, compared with net income of $1.45 billion and earnings per share (EPS) of $1.61 in Q3 2022. EPS in Q3 2023 was inclusive of an increase of $1.22 of EPS associated with the sale of rights for the olanzapine portfolio, as well as a decrease of $3.29 from acquired IPR&D charges, compared with a decrease of $0.06 from acquired IPR&D charges in Q3 2022.

Company Overview

Eli Lilly and Company was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. The company discover, develop, manufacture, and market products in a single business segment—human pharmaceutical products. The company manufacture and distribute its products through facilities in the United States (U.S.), including Puerto Rico, and 7 other countries. The company's products are sold in approximately 110 countries.⁴

Products

Diabetes products

Basaglar
Humalog
Humulin
Jardiance
Mounjaro
Trulicity

Oncology products

Alimta
Cyramza
Erbitux
Jaypirca
Retevmo
Tyvyt
Verzenio

Immunology products

Olumiant
Taltz

Neuroscience products

Cymbalta
Emgality
Zyprexa

Other products and therapies

Bamlanivimab and etesevimab
Bebtelovimab
Cialis
Forteo

Company History

Colonel Eli Lilly, a pharmaceutical chemist and Civil War veteran, founds the company in Indianapolis, Indiana. He starts by producing high-quality medicines in an era of unreliable elixirs.⁵

Year	Milestone
1917	Lilly set up a medical field hospital in France,
1923	Lilly introduced Iletin ® (animal-source insulin, Lilly), the world’s first commercially available insulin product, for the treatment of diabetes
1928	Lilly introduced a liver-extract product to treat pernicious anemia, a life-threatening blood disorder, that served as a standard of therapy for decades
1937	Lilly family members established the Lilly Endowment to pursue personal philanthropic efforts.
1940	Lilly was among the first companies to develop a method to mass-produce Penicillin-G, the world’s first widely available antibiotic
1955	Lilly was the first company to manufacture and distribute the Salk Polio Vaccine globally.
1958	Lilly introduced Vancocin ® (vancomycin hydrochloride, Lilly), an antibiotic for infections associated with certain types of resistant bacteria.
1961	Velban ® (vinblastine, Lilly), the company’s first oncology drug, was introduced for treatment of several types of cancer.
1982	Lilly introduced Humulin ® (human insulin derived from rDNA, Lilly), insulin identical to that produced by the human body, and the world’s first human-health-care product created using recombinant DNA technology.
1986	Lilly introduced Prozac ® (fluoxetine hydrochloride, Lilly) in Belgium as a treatment of clinical depression.
1996	Lilly introduced Gemzar ® (gemcitabine hydrochloride, Lilly) a drug for the treatment of pancreatic and non-small-cell lung cancer.
2004	Lilly introduced Cymbalta ® (duloxetine hydrochloride, Lilly) as a treatment for major depressive disorder.
2019	Lilly makes its largest acquisition to date, purchasing Loxo Oncology to broaden treatment options for patients with cancer through first-in-class and best-in-class medicines.